Overview
This study is a Prospective, Multicenter, non-interventive Real-world Study to evaluate the efficacy and safety of the treatment of Serplulimab in patients with Advanced,Recurrent and Metastatic Cervical Cancer. Approximately 118 eligible subjects are planned to be enrolled across all sites.
Eligibility
Inclusion Criteria:
- Age ≥ 18 years at time of study entry.
- Histologically or cytologically confirmed advanced, recurrent or metastatic cervical cancer.
- Received at least 1 prior systemic therapies in the recurrent or metastatic setting. Tumor progression or recurrence after treatment with therapy.
- ECOG performance status of 0 or 1.
- Patient must have at least one measurable disease as defined by RECIST 1.1.
- Ability to provide written and signed informed consent.
Exclusion Criteria:
- Pregnant or lactating women.
- Life expectancy < 3 months
- Ongoing participation in another clinical study, or planned initiation of treatment in this study less than 14 days from the end of treatment in the previous clinical study.
- Known history of serious allergy to any active ingredie or any excipients list in monoclonal antibody.
- The patient has other factors that, in the judgment of the investigator, may lead to forced early termination of the study.